Business
Half-year Report
Verici Dx plc reported its unaudited interim results for the six months ended June 30, 2025, showing revenue of $1.9 million, including $1.16 million from Tutivia™ testing revenues and $0.75 million from Thermo Fisher licensing revenues. The EBITDA loss was $2.8 million, and the net cash outflow from operating activities was $3.5 million. The company's cash balance as of June 30, 2025, was $0.5 million, increasing to approximately $5.3 million by September 30, 2025. Post period end, Verici Dx raised £6.35 million (gross) to support revenue scaling, extending the cash runway into the second half of 2026. 591 Tutivia™ tests were ordered in H1 2025. Disclaimer*
About this update from Verici Dx Plc
[{"type":"text","content":"\n\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\") \n \nHalf-year report\n \nSignificant commercial progress with first revenues from Tutivia™ test sales\n \nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its unaudited interim results for the six months ended 30 June 2025 (\"H1 2025\"). The first half was a period of significant commercial progress, with two products now fully validated and commercially available, and the first revenues from lead product Tutivia™ recognised.\n \nPost period end the Company raised £6.35m (gross) to support the scale up of revenues, extending the expected cash runway into H2 2026.\n \nComparative unaudited data is for the six months ended 30 June 2024 (\"H1 2024\") unless stated otherwise.\n \nFinancial highlights\n· Revenue of $1.9m (H1 2024: $3.3m; FY 2024: $3.3m)\n§ $1.16m from Tutivia™ testing revenues\n§ $0.75m from Thermo Fisher licensing revenues\n· EBITDA loss of $2.8m (H1 2024: EBITDA loss of $1.1m; FY 2024: EBITDA loss of $5.4m)\n· $0.5m cash balance as at 30 June 2025 (31 December 2024: $4.1m) with cash balance as at 30 September of c.$5.3m\n· Net cash outflow from operating activities in H1 2025 was $3.5m (H1 2024: $3.2m outflow; FY 2024: $6.0m outflow)\n \nOperational highlights\n· Two products now validated and commercially available\n· Lead product Tutivia™ attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway\n· Increasing test adoption: 591 Tutivia™ tests ordered in H1 2025 (334 for the whole of FY 2024)\n· In the period the Company reached a total of 21 transplant centres onboarded - representing 10% of annual US transplant volume\n· Continued progress with the Thermo Fisher Pre-Transplant Risk Assessment Test (PTRA) license\n· Well poised for growth: significant testing volume acceleration expected in H2 2025 and beyond\n· Commercial team expanded post period with the addition of two sales people in place and a director of clinical partnerships to join shortly\n \nCo...